{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:59:14Z","timestamp":1769147954328,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170262"],"award-info":[{"award-number":["81170262"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12944-018-0923-1","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T09:55:12Z","timestamp":1543830912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study"],"prefix":"10.1186","volume":"17","author":[{"given":"Wen","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"issue":"5","key":"923_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","volume":"8","author":"TA Jacobson","year":"2014","unstructured":"Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8(5):473\u201388.","journal-title":"J Clin Lipidol"},{"issue":"9943","key":"923_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(14)61009-6","volume":"384","author":"PM Ridker","year":"2014","unstructured":"Ridker PM. LDL cholesterol: controversies and future therapeutic directions. Lancet. 2014;384(9943):607\u201317.","journal-title":"Lancet"},{"issue":"9753","key":"923_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2008000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"7","key":"923_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11886-016-0743-8","volume":"18","author":"M Farnier","year":"2016","unstructured":"Farnier M. Future lipid-altering therapeutic options targeting residual cardiovascular risk. Curr Cardiol Rep. 2016;18(7):65.","journal-title":"Curr Cardiol Rep"},{"issue":"12","key":"923_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"key":"923_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626\u201335.","journal-title":"Lancet"},{"key":"923_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0140-6736(14)61217-4","volume":"384","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384:618\u201325.","journal-title":"Lancet"},{"issue":"21","key":"923_CR8","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109\u201322.","journal-title":"N Engl J Med"},{"issue":"17","key":"923_CR9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374.","journal-title":"N Engl J Med"},{"issue":"24","key":"923_CR10","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367.","journal-title":"N Engl J Med"},{"issue":"4","key":"923_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"OT Investigators","year":"2012","unstructured":"Investigators OT, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309\u201318.","journal-title":"N Engl J Med"},{"issue":"20","key":"923_CR12","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933\u201342.","journal-title":"N Engl J Med"},{"issue":"17","key":"923_CR13","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","volume":"34","author":"Group HTC","year":"2013","unstructured":"Group HTC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279\u201391.","journal-title":"Eur Heart J"},{"key":"923_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345\u201352.","journal-title":"Nat Genet"},{"issue":"1","key":"923_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"923_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB Jorgensen","year":"2014","unstructured":"Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32\u201341.","journal-title":"N Engl J Med"},{"issue":"1","key":"923_CR17","doi-asserted-by":"publisher","first-page":"7726","DOI":"10.1038\/s41598-018-25835-5","volume":"8","author":"W Dai","year":"2018","unstructured":"Dai W, Long J, Cheng Y, Chen Y, Zhao S. Elevated plasma lipoprotein (a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease. Sci Rep. 2018;8(1):7726.","journal-title":"Sci Rep"},{"issue":"38","key":"923_CR18","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949\u20133003.","journal-title":"Eur Heart J"},{"issue":"10","key":"923_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.7326\/0003-4819-157-10-201211200-00010","volume":"157","author":"A Qaseem","year":"2012","unstructured":"Qaseem A, Fihn SD, Williams S, Dallas P, Owens DK, Shekelle P. Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians\/American College of Cardiology Foundation\/American Heart Association\/American Association for Thoracic Surgery\/preventive cardiovascular nurses association\/Society of Thoracic Surgeons. Ann Intern Med. 2012;157(10):729\u201334.","journal-title":"Ann Intern Med"},{"issue":"3","key":"923_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0002-9149(83)80105-2","volume":"51","author":"GG Gensini","year":"1983","unstructured":"Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.","journal-title":"Am J Cardiol"},{"issue":"2","key":"923_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","volume":"235","author":"S Zhao","year":"2014","unstructured":"Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia international study (DYSIS). Atherosclerosis. 2014;235(2):463\u20139.","journal-title":"Atherosclerosis"},{"issue":"2","key":"923_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.atherosclerosis.2013.12.003","volume":"233","author":"SP Zhao","year":"2014","unstructured":"Zhao SP, Yu BL, Peng DQ, Huo Y. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial. Atherosclerosis. 2014;233(2):707\u201312.","journal-title":"Atherosclerosis"},{"issue":"12","key":"923_CR23","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","volume":"101","author":"Z Lu","year":"2008","unstructured":"Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101(12):1689\u201393.","journal-title":"Am J Cardiol"},{"issue":"9","key":"923_CR24","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","volume":"32","author":"P Libby","year":"2012","unstructured":"Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"923_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836\u201343.","journal-title":"N Engl J Med"},{"issue":"16","key":"923_CR26","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685\u201395.","journal-title":"N Engl J Med"},{"issue":"1","key":"923_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"923_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cmet.2011.07.015","volume":"14","author":"KE Bornfeldt","year":"2011","unstructured":"Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575\u201385.","journal-title":"Cell Metab"},{"issue":"1","key":"923_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10741-015-9515-6","volume":"21","author":"TP Patel","year":"2016","unstructured":"Patel TP, Rawal K, Bagchi AK, Akolkar G, Bernardes N, Dias Dda S, et al. Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev. 2016;21(1):11\u201323.","journal-title":"Heart Fail Rev"},{"issue":"6","key":"923_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/CRD.0000000000000113","volume":"24","author":"BM Lilleness","year":"2016","unstructured":"Lilleness BM, Frishman WH. Ghrelin and the cardiovascular system. Cardiol Rev. 2016;24(6):288\u201397.","journal-title":"Cardiol Rev"},{"key":"923_CR31","volume-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines 2018."},{"issue":"18","key":"923_CR32","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1161\/CIRCULATIONAHA.111.065904","volume":"125","author":"W Yang","year":"2012","unstructured":"Yang W, Xiao J, Yang Z, Ji L, Jia W, Weng J, et al. Serum lipids and lipoproteins in Chinese men and women. Circulation. 2012;125(18):2212\u201321.","journal-title":"Circulation"},{"issue":"11","key":"923_CR33","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","volume":"128","author":"RS Rosenson","year":"2013","unstructured":"Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128(11):1256\u201367.","journal-title":"Circulation"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-018-0923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-018-0923-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-018-0923-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T19:07:05Z","timestamp":1575313625000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-018-0923-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1186\/s12944-018-0923-1","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"29 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee review board of The Second Xiangya Hospital of Central South University. Informed written consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"273"}}